Xenical Diabetes Risk Reduction Data Added To Labeling
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche weight loss drug adds data from the XENDOS trial showing ability to delay onset of type 2 diabetes in obese patients with impaired glucose tolerance. Change could help Roche increase reimbursement for Xenical.